Generali Asset Management SPA SGR Purchases New Shares in Solventum Co. (NYSE:SOLV)

Generali Asset Management SPA SGR bought a new stake in shares of Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,983 shares of the company's stock, valued at approximately $659,000.

Several other hedge funds have also recently made changes to their positions in SOLV. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum during the 3rd quarter valued at about $125,488,000. Trian Fund Management L.P. raised its holdings in shares of Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company's stock valued at $496,842,000 after buying an additional 1,765,676 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Solventum in the 3rd quarter worth approximately $50,948,000. Nordea Investment Management AB grew its position in Solventum by 189.5% during the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock valued at $43,902,000 after acquiring an additional 431,986 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Solventum during the fourth quarter worth approximately $18,583,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SOLV shares. Mizuho boosted their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. The Goldman Sachs Group boosted their target price on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Piper Sandler raised their price target on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Bank of America boosted their price objective on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. Finally, Morgan Stanley increased their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $79.86.

Remove Ads

Solventum Trading Up 0.9 %

Solventum stock traded up $0.67 during mid-day trading on Tuesday, reaching $74.87. 1,083,684 shares of the company traded hands, compared to its average volume of 1,427,904. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm has a market capitalization of $12.95 billion and a price-to-earnings ratio of 27.23. The firm's 50 day moving average price is $75.29 and its 200 day moving average price is $71.67.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.